Match!
Michael R. Migden
University of Texas MD Anderson Cancer Center
PathologyBasal cell carcinomaVismodegibSonidegibMedicine
88Publications
16H-index
2,027Citations
What is this?
Publications 86
Newest
#1Danny Rischin (Peter MacCallum Cancer Centre)H-Index: 52
#2Michael R. Migden (University of Texas MD Anderson Cancer Center)H-Index: 16
Last. Anne Lynn S. Chang (Stanford University)H-Index: 29
view all 28 authors...
Background Cemiplimab, a high-affinity, potent human immunoglobulin G4 monoclonal antibody to programmed cell death-1 demonstrated antitumor activity in a Phase 1 advanced cutaneous squamous cell carcinoma (CSCC) expansion cohort (NCT02383212) and the pivotal Phase 2 study (NCT02760498). Here we report the primary analysis of fixed dose cemiplimab 350 mg intravenously every 3 weeks (Q3W) (Group 3) and provide a longer-term update after the primary analysis of weight-based cemiplimab 3 mg/kg intr...
Source
#1Reinhard Dummer (UZH: University of Zurich)H-Index: 101
#2A. Guminksi (USYD: University of Sydney)H-Index: 1
Last. Michael R. Migden (University of Texas MD Anderson Cancer Center)H-Index: 16
view all 17 authors...
BACKGROUND: Basal cell carcinomas (BCCs) exhibit aberrant activation of the hedgehog pathway. Sonidegib is a hedgehog pathway inhibitor approved for the treatment of locally advanced BCC (laBCC) and metastatic BCC (mBCC) based on primary results of the BOLT study [Basal Cell Carcinoma Outcomes with LDE225 (sonidegib) Treatment]. OBJECTIVES: This is the final 42-month analysis of the BOLT study, evaluating the efficacy and safety of sonidegib. METHODS: Adults with no prior hedgehog pathway inhibi...
4 CitationsSource
#1Danny Rischin (Peter MacCallum Cancer Centre)H-Index: 52
Last. Dirk SchadendorfH-Index: 102
view all 19 authors...
10018Background: Cemiplimab monotherapy achieves clinically meaningful activity in pts with advanced CSCC (metastatic [mCSCC] or locally advanced [laCSCC] not amenable to curative surgery or curati...
Source
#1Michael R. Migden (University of Texas MD Anderson Cancer Center)H-Index: 16
#2Danny Rischin (Peter MacCallum Cancer Centre)H-Index: 52
view all 17 authors...
Source
#1Samantha Tam (University of Texas MD Anderson Cancer Center)H-Index: 9
#2Christopher M. K. L. Yao (University of Texas MD Anderson Cancer Center)H-Index: 3
Last. Neil Gross (University of Texas MD Anderson Cancer Center)H-Index: 10
view all 21 authors...
Importance Patients with immunosuppression have a higher incidence of cutaneous squamous cell carcinoma (cSCC) and often present with more aggressive, multifocal disease. Objectives To determine the risks for mortality in patients with cSCC and immunosuppression compared with nonimmunosuppression and to compare the difference in mortality risk based on the cause of immunocompromise. Design, Setting, and Participants This retrospective cohort study of patients with cSCC of the head and neck recru...
Source
#1Michael R. Migden (University of Texas MD Anderson Cancer Center)H-Index: 16
Last. Danny Rischin (Peter MacCallum Cancer Centre)H-Index: 52
view all 22 authors...
Summary Background Cemiplimab has shown substantial antitumour activity in patients with metastatic cutaneous squamous cell carcinoma. Patients with locally advanced cutaneous squamous cell carcinoma have poor prognosis with conventional systemic therapy. We present a primary analysis of the safety and antitumour activity of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma. Methods This pivotal open-label, phase 2, single-arm trial was done across 25 outpatient clin...
4 CitationsSource
#1Leon Chen (University of Texas MD Anderson Cancer Center)H-Index: 2
#1Leon ChenH-Index: 1
Last. Michael R. Migden (University of Texas MD Anderson Cancer Center)H-Index: 16
view all 3 authors...
As the most common cancer in humans, basal cell carcinomas (BCCs) affect approximately 2.8 million people. Depending on the location, size, tumor subtype, and other factors, treatment may include topical therapy with imiquimod or 5-fluorouracil, cryotherapy, radiation, photodynamic therapy, electrodesiccation and curettage, surgical excision, and Mohs micrographic surgery, the latter of which has the lowest 5-year recurrence rate: between 0.7% and 2.4%. BCC is mainly a localized neoplasm, althou...
Source
Source
#1Michael R. Migden (University of Texas MD Anderson Cancer Center)H-Index: 16
#2Sunandana Chandra (NU: Northwestern University)H-Index: 13
Last. Emily Stamell Ruiz (Brigham and Women's Hospital)H-Index: 7
view all 14 authors...
In 2018, cemiplimab-rwlc became the first systemic treatment approved by the US FDA for patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. In 2019, conditional approvals were granted by Health Canada and the European Commission for the same indications. Limited data exist pertaining to the clinical characteristics, disease progression and survivorship of patients with advanced CSCC in real-...
Source
#1Leon Chen (University of Texas MD Anderson Cancer Center)H-Index: 2
#1Leon ChenH-Index: 1
Last. Michael R. Migden (University of Texas MD Anderson Cancer Center)H-Index: 16
view all 3 authors...
Non-melanoma skin cancer (NMSC) is the most common cancer diagnosis in the United States. Approximately 3.3 million people are diagnosed with a total of 5.4 million NSMCs annually. Basal cell carcinoma (BCC) is the most common type of NMSC; however, cancer registries do not collect information on BCC, and thus the data regarding its prevalence and true incidence are not obtainable. Previous population-based studies estimated the age-standardized annual incidence of BCC in both Caucasian men and ...
Source
123456789